Premium
Protein‐conjugated acrolein as a biochemical marker of brain infarction
Author(s) -
Igarashi Kazuei,
Kashiwagi Keiko
Publication year - 2011
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201100068
Subject(s) - acrolein , spermine , chemistry , polyamine , infarction , cerebral infarction , stroke (engine) , biochemistry , medicine , myocardial infarction , enzyme , ischemia , mechanical engineering , engineering , catalysis
The relationship between acrolein (CH 2 =CH‐CHO) and brain infarction is the focus of this review. It has been found that acrolein is produced mainly within cells from polyamines by polyamine oxidases (PAOs), especially from spermine by spermine oxidase during cell damage, and that acrolein is more toxic than reactive oxygen species (ROS) in a cell culture system. Thus, the possibility that acrolein and PAOs are good biochemical markers of stroke was tested because there are no other reliable biochemical markers at the early stage of stroke. Levels of protein‐conjugated acrolein (PC‐Acro) and PAOs (acrolein‐producing enzymes) were significantly increased in the plasma of stroke patients. The multiplied value of PC‐Acro by PAOs was nearly parallel with the size of stroke. Furthermore, when the combined measurements of PC‐Acro, interleukin‐6 (IL‐6) and C‐reactive protein (CRP) were evaluated along with age using a receiver operating characteristic (ROC) curve, even silent brain infarction (SBI), which is a small brain infarction, was indicated with approximately 84% sensitivity and specificity. These findings clearly indicate that acrolein is strongly correlated with cell damage during brain infarction.